Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 23Andme Holding Co. (NQ: ME ) 0.3883 +0.0193 (+5.23%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about 23Andme Holding Co. < Previous 1 2 3 4 5 6 7 8 9 Next > Legal Battle Brews Over 23andMe's Customer Data Breach Settlement And Arbitration Claimants October 02, 2024 Lawyer raises objections to 23andMe's proposed $30 million settlement, arguing it undermines arbitration rights for 5,000 customers following a data breach. The court is set to review the case in late... Via Benzinga Topics Data Breach Exposures Information Security 12 Health Care Stocks Moving In Friday's After-Market Session September 27, 2024 Via Benzinga 23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating September 25, 2024 Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics From 23andMe, Inc. Via GlobeNewswire Independent Board Members Of Penny Stock 23andMe Resign, Call Out CEO Anne Wojcicki For Not 'Actionable Proposal' Despite Ample Time September 18, 2024 23andMe's independent board members resigned after months of waiting for Anne Wojcicki's fully financed proposal to take the company private. Via Benzinga Looking Into 23andMe Holding's Recent Short Interest June 12, 2024 Via Benzinga General Mills, Steelcase And 3 Stocks To Watch Heading Into Wednesday September 18, 2024 Via Benzinga Independent Directors of 23andMe Resign from Board September 17, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial September 15, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study September 15, 2024 From 23andMe, Inc. Via GlobeNewswire One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations September 12, 2024 23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse population From 23andMe, Inc. Via GlobeNewswire 23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024 September 03, 2024 From 23andMe, Inc. Via GlobeNewswire Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket August 29, 2024 Via Benzinga Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program August 28, 2024 In conjunction with this new offering, 23andMe, Lemonaid Health’s parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s From 23andMe, Inc. Via GlobeNewswire ME Stock Earnings: 23andMe Holding Beats EPS, Misses Revenue for Q1 2025 August 08, 2024 ME stock results show that 23andMe Holding beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025. Via InvestorPlace 23andMe Reports First Quarter Fiscal 2025 Financial Results August 08, 2024 From 23andMe, Inc. Via GlobeNewswire ME Stock Alert: CEO Anne Wojcicki Enters $200 Million Buyout Offer for 23andMe August 02, 2024 23andMe stock is up on Friday as investors react to an offer from the company's founder to take it private for 40 cents per share for ME. Via InvestorPlace 23andMe Special Committee responds to CEO’s take-private proposal August 02, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe Announces CEO’s Take-Private Proposal August 01, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe to Report Q1 FY2025 Financial Results July 25, 2024 From 23andMe, Inc. Via GlobeNewswire Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research July 25, 2024 Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer From 23andMe, Inc. Via GlobeNewswire The 3 Best Personalized Nutrition Stocks to Buy Now July 24, 2024 Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions. Via InvestorPlace Topics Artificial Intelligence Exposures Artificial Intelligence 23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME July 19, 2024 From Kahn Swick & Foti, LLC Via Business Wire 3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts July 11, 2024 Hercules Capital, Pfizer and Target offer stability, growth potential and reliable dividends in the realm of high-dividend stocks. Via InvestorPlace 23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel June 28, 2024 From 23andMe, Inc. Via GlobeNewswire 3 Ultra-High-Yield Dividend Stocks to Buy Hand Over Fist Right This Instant June 27, 2024 Business development companies can be a lucrative source of passive income. Via The Motley Fool 3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition June 11, 2024 Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. Via InvestorPlace 23andMe Launches New Genetic Report on Bipolar Disorder June 05, 2024 Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variants From 23andMe, Inc. Via GlobeNewswire Why 23andMe Stock Tumbled 10% on Tuesday June 04, 2024 Is altruism a good idea for an unprofitable capitalistic enterprise? Via The Motley Fool 23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community June 04, 2024 Study aims to fill research gap and empower people through access to information about their health From 23andMe, Inc. Via GlobeNewswire 23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting June 03, 2024 From 23andMe, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.